Nanobiotix

Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer

Nanobiotix completed a sub-10% private placement by issuing new shares to US and EU institutional investors
Proceeds will be used for the development of lead product NBTXR3 and preparation of its market access and launch
Order book was of mainly long-only demand was covered by a majority of new institutional investors and institutional investors from the US